Avid Bioservices to Join S&P SmallCap 600 Index
26 Outubro 2021 - 9:05AM
Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics
contract development and manufacturing organization (CDMO) working
to improve patient lives by providing high quality development and
manufacturing services to biotechnology and pharmaceutical
companies, today announced that the company will be added to the
S&P SmallCap 600 Index, effective prior to the open of trading
on Friday, October 29, 2021.
“We are pleased to be added to the S&P
SmallCap 600 Index as it is a further demonstration of the momentum
that Avid continues to generate as we successfully execute against
our comprehensive growth strategy. This recognition is also an
important testament to the hard work and key contributions that
every member of the Avid team has made to the company’s ongoing
success,” said Nick Green, president and chief executive officer
of Avid Bioservices.
The S&P SmallCap 600 Index is a stock
market index established by Standard & Poor's that is
designed to measure the performance of the small-cap segment of the
market and is composed of 600 constituent companies in the U.S.
equities market. The index is designed to track companies that meet
specific inclusion criteria to ensure that they are liquid and
financially viable. To be included, companies must have an
unadjusted market cap in the range of $850 million to $3.6
billion.
About Avid
Bioservices, Inc.
Avid Bioservices is a dedicated contract
development and manufacturing organization (CDMO) focused on
development and CGMP manufacturing of biologics. The company
provides a comprehensive range of process development, CGMP
clinical and commercial manufacturing services for the
biotechnology and biopharmaceutical industries. With 28 years of
experience producing monoclonal antibodies and recombinant
proteins, Avid's services include CGMP clinical and commercial drug
substance manufacturing, bulk packaging, release and stability
testing and regulatory submissions support. For early-stage
programs the company provides a variety of process development
activities, including upstream and downstream development and
optimization, analytical methods development, testing and
characterization. The scope of our services ranges from
standalone process development projects to full development and
manufacturing programs through commercialization.
www.avidbio.com
Contacts:
Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
sdiaz@vidasp.com
Tim Brons (Media)
Vida Strategic Partners
415-675-7402
tbrons@vidasp.com
Avid Bioservices (NASDAQ:CDMOP)
Gráfico Histórico do Ativo
De Set 2024 até Out 2024
Avid Bioservices (NASDAQ:CDMOP)
Gráfico Histórico do Ativo
De Out 2023 até Out 2024